1
|
Kaidarova D, Zhavrid E, Shatkovskaya O, Prokharau A, Akhmed N, Sembayev D, Rutzhanova Z, Ivankov A. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial. Cancer Treat Res Commun 2024; 40:100817. [PMID: 38735220 DOI: 10.1016/j.ctarc.2024.100817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 04/29/2024] [Accepted: 04/29/2024] [Indexed: 05/14/2024]
Abstract
AIM To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin) administered either with a single-use injection device (SID) or manually from a vial using a hand-held syringe. METHODS The ESCAPE trial (NCT02194166) included 90 women aged 18 years or older with HER2-positive early breast cancer who underwent surgical treatment and completed (neo) adjuvant chemotherapy and radiotherapy (if indicated). Patients enrolled in the study were first subjected to 4 cycles of trastuzumab IV (8 mg/kg loading dose followed by 6 mg/kg maintenance dose, q3w) prior to being randomized into groups: [A] SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID or [B] the reverse sequence. RESULTS Patient-reported outcomes revealed that 78 (94.0 % [95 % CI: 90.4-99.0]) out of 83 patients preferred SC trastuzumab over IV trastuzumab, among whom 28 patients indicated a strong preference. Sixteen out of 17 HCPs (94.1 %) were very satisfied with the use of SC trastuzumab, while 1/17 (5.9 %) remained uncertain. The mean time spent for IV vs. SC trastuzumab administration, including pre- and postinjection procedures, was 93.8 and 22 min, respectively. A total of 49 (54.4 %) patients reported 164 AEs. CONCLUSIONS In this trial, SC trastuzumab was preferred over IV trastuzumab. The duration of SC trastuzumab administration was significantly shorter than that of IV trastuzumab, saving patients and HCPs time. Safety and efficacy results were consistent with other published trials and were not associated with any new safety signal.
Collapse
Affiliation(s)
- Dilyara Kaidarova
- Kazakh Institute of Oncology and Radiology of the Ministry of Health of the Republic of Kazakhstan, Almaty, Kazakhstan
| | - Edvard Zhavrid
- N.N.Alexandrov National Cancer Center of Belarus, Belarus
| | - Oxana Shatkovskaya
- Kazakh Institute of Oncology and Radiology of the Ministry of Health of the Republic of Kazakhstan, Almaty, Kazakhstan
| | - Aliaksandr Prokharau
- Minsk Clinical Cancer Center/Department of Oncology, Belarusian State Medical University, Minsk, Belarus
| | - Nina Akhmed
- N.N.Alexandrov National Cancer Center of Belarus, Belarus
| | - Dauren Sembayev
- Department of Chemotherapy, Multidisciplinary Medical Center of Akimat of Astana, Astana, Kazakhstan
| | - Zhanna Rutzhanova
- Department of Chemotherapy, Multidisciplinary Medical Center of Akimat of Astana, Astana, Kazakhstan
| | | |
Collapse
|
2
|
Krasny S, Polyakov S, Zhavrid E, Khorau A, Baranau Y, Kozlovskaya S, Sergeeva O, Zharkova K, Sufianov A, Gabai V, Shneider A. 278P Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.561] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
3
|
Polyakov S, Krasny S, Zhavrid E, Baranau Y, Sergeeva O, Zharkova K, Khorau A, Kozlovskaya S, Gabai V, Shneider A. 759P Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Kwak LW, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Menne T, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Ogura M, Kim WS, Lee SJ, Kim SH, Ahn KY, Buske C. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Clin Lymphoma Myeloma Leuk 2021; 22:89-97. [PMID: 34686445 DOI: 10.1016/j.clml.2021.08.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 08/05/2021] [Accepted: 08/22/2021] [Indexed: 12/29/2022]
Abstract
INTRODUCTION This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. PATIENTS AND METHODS LTBFL patients were randomized (1:1) to receive CT-P10 or rituximab (375 mg/m2 intravenously; day 1 of 4 7-day cycles). Patients achieving disease control entered a 2-year maintenance period. CT-P10 or rituximab were administered every 8 weeks (6 cycles) in year 1; all patients could receive CT-P10 (every 8 weeks; 6 cycles) in year 2. Secondary endpoints (reported here) were overall response rate (ORR) during the study period, progression-free survival (PFS), time to progression (TTP), and overall survival (OS). Safety and immunogenicity were evaluated. RESULTS Between November 9, 2015 and January 4, 2018, 258 patients were randomized (130 for CT-P10; 128 for rituximab). ORR was similar between groups over the study period (CT-P10: 88%; rituximab: 87%). After 29.2 months' median follow-up, median PFS, TTP, and OS were not estimable; 24-month Kaplan-Meier estimates suggested similarity between groups. Overall, 114 (CT-P10: 88%), and 104 (rituximab: 81%) patients experienced treatment-emergent adverse events. The single switch was well tolerated. CONCLUSION These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 monotherapy for previously untreated LTBFL.
Collapse
Affiliation(s)
| | - Juan-Manuel Sancho
- Hematology Department, The Catalan Institute of Oncology-The Josep Carreras Leukemia Research Institute, Hospital Germans Trias i Pujol, Carretera Canyet, Badalona, 08916, Spain
| | - Seok-Goo Cho
- Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, 06591, South Korea
| | - Hideyuki Nakazawa
- Department of Hematology, Shinshu University School of Medicine, Nagano 390-8621, Japan
| | - Junji Suzumiya
- Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Shimane 693-8501, Japan
| | - Gayane Tumyan
- Division of Hematology and Bone Marrow Transplantation, N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Science, Moscow, 115478, Russia
| | - Jin Seok Kim
- Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, 03722, South Korea
| | - Tobias Menne
- Northern Institute for Cancer Care, Newcastle University, NE7 7DN, UK
| | - José Mariz
- Department of Onco-Hematology, Portuguese Institute of Oncology, Rua Dr Antonio Bernardino de Almeida, Porto, 4200-072, Portugal
| | - Nikolai Ilyin
- Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, p. Pesochny, 197758, Russia
| | - Wojciech Jurczak
- Maria Sklodowska-Curie National Research Institute of Oncology, 331-115 Kraków, Poland
| | - Aurelio Lopez Martinez
- Department of Hematology, Hospital Arnau de Vilanova, Valencia, Comunidad Valenciana, 46015, Spain
| | - Olga Samoilova
- Department of Hematology, Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, 603126, Russia
| | - Edvard Zhavrid
- N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Lesnoy, Minsk, 223040, Belarus
| | - Eduardo Yañez Ruiz
- Department of Internal Medicine, Oncology-Hematology Unit, School of Medicine, Universidad de la Frontera, Temuco, 4780000, Chile
| | - Marek Trneny
- Department of Medicine, Charles University, 128 08, Czech Republic
| | - Leslie Popplewell
- Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA 91010
| | - Michinori Ogura
- Department of Hematology and Oncology, Kasugai Municipal Hospital, Aichi 486-8510, Japan
| | - Won-Seog Kim
- Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06355, South Korea
| | | | | | | | - Christian Buske
- Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm, University Hospital of Ulm, 89081 Ulm, Germany.
| |
Collapse
|
5
|
Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. JAMA Oncol 2020; 6:e193531. [PMID: 31600365 PMCID: PMC6802061 DOI: 10.1001/jamaoncol.2019.3531] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Question Is trifluridine/tipiracil treatment safe and effective for the subpopulation of patients with previously treated metastatic gastric or gastroesophageal junction cancer who have undergone gastrectomy? Findings In this subgroup analysis of a randomized clinical trial, trifluridine/tipiracil treatment improved overall survival and progression-free survival compared with placebo among patients with previously treated metastatic gastric or gastroesophageal junction cancer and who had or had not undergone gastrectomy. No new safety concerns were reported, and hematologic toxic effects were more frequent among the subgroup who had undergone gastrectomy but were treated using dosing modifications. Meaning Trifluridine/tipiracil is a safe and effective treatment option for patients with pretreated metastatic gastric or gastroesophageal junction cancer regardless of previous gastrectomy. Importance Trifluridine/tipiracil (FTD/TPI) treatment has shown clinical benefit in patients with pretreated metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC). Patients who have undergone gastrectomy constitute a significant proportion of patients with mGC/GEJC. Objective To assess the efficacy and safety of FTD/TPI among patients with previously treated mGC/GEJC who had or had not undergone gastrectomy. Design, Setting, and Participants This preplanned subgroup analysis of TAGS (TAS-102 Gastric Study), a phase 3, randomized, placebo-controlled, clinical trial included patients with mGC/GEJC who had received at least 2 previous chemotherapy regimens, and was conducted at 110 academic hospitals in 17 countries in Europe, Asia, and North America, with enrollment between February 24, 2016, and January 5, 2018; the data cutoff was March 31, 2018. Interventions Patients were randomized 2:1 to receive oral FTD/TPI 35 mg/m2 twice daily or placebo twice daily with best supportive care on days 1 through 5 and days 8 through 12 of each 28-day treatment cycle. Main Outcomes and Measures The primary end point was overall survival. This subgroup analysis was conducted to examine potential trends and was not powered for statistical significance. Efficacy and safety end points were evaluated in the subgroups. Results Of 507 randomized patients (369 [72.8%] male; mean [SD] age, 62.5 [10.5] years), 221 (43.6%) had undergone gastrectomy (147 randomized to FTD/TPI and 74 to placebo) and 286 (56.4%) had not undergone gastrectomy (190 randomized to FTD/TPI and 96 to placebo). In the gastrectomy subgroup, the overall survival hazard ratio (HR) in the FTD/TPI group vs placebo group was 0.57 (95% CI, 0.41-0.79), and the progression-free survival HR was 0.48 (95% CI, 0.35-0.65). In the no gastrectomy subgroup, the overall survival HR in the FTD/TPI group vs placebo group was 0.80 (95% CI, 0.60-1.06), and the progression-free survival HR was 0.65 (95% CI, 0.49-0.85). Among FTD/TPI-treated patients, grade 3 or higher adverse events of any cause occurred in 122 of 145 patients (84.1%) in the gastrectomy subgroup and 145 of 190 (76.3%) in the no gastrectomy subgroup: 64 (44.1%) in the gastrectomy subgroup and 50 (26.3%) in the no gastrectomy subgroup had grade 3 or higher neutropenia, 31 (21.4%) in the gastrectomy subgroup and 33 (17.4%) in the no gastrectomy subgroup had grade 3 or higher anemia, and 21 (14.5%) in the gastrectomy subgroup and 10 (5.3%) in the no gastrectomy subgroup hD grade 3 or higher leukopenia. In the gastrectomy subgroup, 94 (64.8%) had dosing modifications because of adverse events vs 101 (53.2%) in the no gastrectomy subgroup; 15 (10.3%) in the gastrectomy group and 28 (14.7%) in the no gastrectomy group discontinued treatment because of adverse events. Treatment exposure was similar between groups. Conclusions and Relevance The FTD/TPI treatment was tolerable and provided efficacy benefits among patients with pretreated mGC/GEJC regardless of previous gastrectomy. Trial Registration ClinicalTrials.gov identifier: NCT02500043
Collapse
Affiliation(s)
- David H Ilson
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Josep Tabernero
- Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Hendrik-Tobias Arkenau
- Drug Development Unit, Sarah Cannon Research Institute, Cancer Institute, University College London, London, United Kingdom
| | - Michele Ghidini
- Department of Oncology, Azienda Ospedaliera di Cremona, Cremona, Italy
| | | | - Eric Van Cutsem
- Digestive Oncology, University Hospitals Gasthuisberg Leuven, KU Leuven, Leuven, Belgium
| | - Peter Thuss-Patience
- Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | | | - Wasat Mansoor
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - Edvard Zhavrid
- Department of Chemotherapy, Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | - Maria Alsina
- Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Ben George
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee
| | - Daniel Catenacci
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Sandra McGuigan
- Medical Affairs Division, Taiho Oncology Inc, Princeton, New Jersey
| | | | - Toshihiko Doi
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - Kohei Shitara
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| |
Collapse
|
6
|
Tabernero J, Alsina M, Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Ando T, Yalçın Ş, Van Cutsem E, Sabater J, Skanji D, Leger C, Amellal N, Ilson DH. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer 2020; 23:689-698. [PMID: 32128634 PMCID: PMC7305098 DOI: 10.1007/s10120-020-01053-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Accepted: 02/17/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with placebo in heavily pretreated metastatic gastric cancer patients. This paper reports pre-specified quality of life (QoL) outcomes for TAGS. METHODS Patients were randomized 2:1 to trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle) plus best supportive care (BSC) or placebo plus BSC. QoL was evaluated at baseline and at each treatment cycle, using the EORTC QLQ-C30 and EORTC QLQ-STO22 questionnaires; results were considered valid for analysis only if ≥ 10% of patients completed the questionnaires. Key QoL outcomes were mean changes from baseline and time to deterioration in QoL. A post hoc analysis assessed the association between QoL and time to deterioration of Eastern Cooperative Oncology Group performance score (ECOG PS) to ≥ 2. RESULTS Of 507 randomized patients, 496 had baseline QoL data available. The analysis cut-off was 6 cycles for trifluridine/tipiracil and 3 cycles for placebo. In both treatment groups, there were no clinically significant deteriorations in the mean QLQ-C30 Global Health Status (GHS) score, or in most subscale scores. In a sensitivity analysis including death and disease progression as events, there was a trend towards trifluridine/tipiracil reducing the risk of deterioration of QoL scores compared with placebo. Deterioration in the GHS score was associated with deterioration in ECOG PS. CONCLUSION QoL was maintained in TAGS, and there was a trend towards trifluridine/tipiracil reducing the risk of QoL deterioration compared with placebo. Trial registration ClinicalTrials.gov number: NCT02500043.
Collapse
Affiliation(s)
- Josep Tabernero
- grid.411083.f0000 0001 0675 8654Vall d’Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain
| | - Maria Alsina
- grid.411083.f0000 0001 0675 8654Vall d’Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain
| | - Kohei Shitara
- grid.497282.2National Cancer Center Hospital East, Chiba, Japan
| | - Toshihiko Doi
- grid.497282.2National Cancer Center Hospital East, Chiba, Japan
| | | | - Wasat Mansoor
- grid.412917.80000 0004 0430 9259The Christie NHS Foundation Trust, Manchester, UK
| | | | | | | | - Catia Faustino
- grid.418711.a0000 0004 0631 0608Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal
| | - Vera Gorbunova
- grid.466904.9N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
| | - Edvard Zhavrid
- Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | | | - Takayuki Ando
- grid.267346.20000 0001 2171 836XUniversity of Toyama, Toyama, Japan
| | - Şuayib Yalçın
- grid.14442.370000 0001 2342 7339Hacettepe University, Ankara, Turkey
| | - Eric Van Cutsem
- grid.410569.f0000 0004 0626 3338University Hospitals and KU Leuven, Leuven, Belgium
| | - Javier Sabater
- grid.418301.f0000 0001 2163 3905Market Access Department, Servier, Suresnes, France
| | - Donia Skanji
- grid.418301.f0000 0001 2163 3905Institut de Recherches Internationales Servier, Suresnes, France
| | - Catherine Leger
- grid.418301.f0000 0001 2163 3905Institut de Recherches Internationales Servier, Suresnes, France
| | - Nadia Amellal
- grid.418301.f0000 0001 2163 3905Institut de Recherches Internationales Servier, Suresnes, France
| | - David H. Ilson
- grid.51462.340000 0001 2171 9952Memorial Sloan Kettering Cancer Center, New York, NY USA
| |
Collapse
|
7
|
Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Lee S, Kim M, Kim S, Park S, Bae J, Esteva F. 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol 2019; 84:839-847. [PMID: 31428820 PMCID: PMC6768896 DOI: 10.1007/s00280-019-03920-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 07/30/2019] [Indexed: 12/12/2022]
Abstract
PURPOSE Neoadjuvant CT-P6, a trastuzumab biosimilar, demonstrated equivalent efficacy to reference trastuzumab in a phase 3 trial of HER2-positive early-stage breast cancer (EBC) (NCT02162667). We report post hoc analyses evaluating pathological complete response (pCR) and breast pCR alongside additional efficacy and safety measures. METHODS Following neoadjuvant treatment and surgery, patients received adjuvant CT-P6 or trastuzumab (6 mg/kg) every 3 weeks for ≤ 1 year. RESULTS In total, 271 and 278 patients received CT-P6 and trastuzumab, respectively. pCR and breast pCR rates were comparable between treatment groups regardless of age, region, or clinical stage. Overall, 47.6% (CT-P6) and 52.2% (trastuzumab) of patients experienced study drug-related treatment-emergent adverse events (TEAEs), including 17 patients reporting heart failure (CT-P6: 10; trastuzumab: 7). Two CT-P6 and three trastuzumab patients discontinued adjuvant treatment due to TEAEs. CONCLUSION Adjuvant CT-P6 demonstrated comparable efficacy and safety to trastuzumab at 1 year in patients with HER2-positive EBC, supporting CT-P6 and trastuzumab comparability.
Collapse
Affiliation(s)
- F J Esteva
- Perlmutter Cancer Center, NYU Langone Health, 160 E 34th Street, New York, 10016, USA.,New York University Langone Medical Center, 550 1st Avenue, New York, 10016, USA
| | - Y V Baranau
- Department of Oncology, Belarusian State Medical University, 220013, Minsk, Belarus
| | - V Baryash
- Department of Oncology, Belarusian State Medical University, 220013, Minsk, Belarus
| | - A Manikhas
- City Clinical Oncology Dispensary, Saint Petersburg, 198255, Russian Federation
| | - V Moiseyenko
- GBUZ Saint Petersburg Clinical Research Center of Specialised Types of Care (Oncology), Saint Petersburg, 197758, Russian Federation
| | - G Dzagnidze
- S. Khechinashvili University Clinic, Ltd, 0177, Tbilisi, Georgia
| | - E Zhavrid
- N.N. Alexandrov National Cancer Centre of Belarus, 223040, Minsk Region, Belarus
| | - D Boliukh
- Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsia, 21029, Ukraine
| | - D Stroyakovskiy
- Moscow City Oncology Hospital, Moscow, 143423, Russian Federation
| | - J Pikiel
- Wojewodzkie Centrum Onkologii, 80-219, Gdańsk, Poland
| | - A E Eniu
- Cancer Institute "Ion Chiricuta", 400015, Cluj-Napoca, Romania
| | - R K Li
- St. Luke's Medical Center, 1102, Quezon City, Philippines
| | - A V Rusyn
- Transcarpathian Regional Clinical Oncology Dispensary, Transcarpathian, 88000, Ukraine
| | - B Tiangco
- The Medical City, Ortigas Avenue, Pasig City, Philippines
| | - S J Lee
- CELLTRION, Inc., Incheon, 22014, Republic of Korea
| | - S Young Lee
- CELLTRION, Inc., Incheon, 22014, Republic of Korea
| | - S Y Yu
- CELLTRION, Inc., Incheon, 22014, Republic of Korea
| | - J Stebbing
- Division of Cancer, Imperial Centre for Translational and Experimental Medicine, Du Cane Road, London, W12 0HS, UK. .,Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF, UK.
| |
Collapse
|
9
|
Alsina M, Tabernero J, Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Ando T, Yalcin S, Van Cutsem E, Skanji D, Leger C, Sabater J, Ilson DH. Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.4043] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4043 Background: The phase 3, randomized, double-blind, placebo-controlled study (TAGS) evaluated the efficacy and safety of FTD/TPI (35 mg/m² given orally twice a day on days 1–5 and 8–12 of a 28-day cycle) in mGC patients who had previously received≥2 prior regimens for advanced disease and demonstrated a clinically relevant and statistically significant benefit in OS and PFS with a predictable and manageable safety profile. HRQoL data and association between QoL and time to ECOG status deterioration (2 or more) are reported here. Methods: HRQoL was evaluated using EORTC QLQ-C30 and the gastric-specific module (QLQ-STO22) questionnaires at baseline and at every 4 weeks thereafter until treatment discontinuation. Prespecified key HRQoL were changes from baseline and time to deterioration. Changes ≥10 points were deemed clinically relevant. A time-dependent Cox-regression analysis was performed to evaluate the association of 10-point Global Health Status deterioration with worsening ECOG status. Results: Of 507 patients randomized, 332/337 (98.5%) of FTD/TPI and 164/170 (96.5%) of placebo had baseline QoL data. Overall compliance was 84% for both questionnaires. Demographic and disease were generally balanced between the two groups; QoL scores were also similar between groups. HRQoL was largely maintained during treatment in both arms for most items; mean changes from baseline remained under the 10-point threshold. Clinically relevant changes from baseline were observed only for pain relief at cycle 2 (favouring FTD/TPI); and improved role functioning at cycle 3 (favouring placebo). In a sensitivity analysis including death or progression as an event, FTD/TPI was associated with a positive trend suggesting a reduced risk of QoL deterioration across all scales compared to placebo (HRs ranged from 0.57 to 0.74. A 10-point Global Health Status deterioration was associated with a worsening ECOG status (HR, 95% CI, 1.5, 1.2 to 1.86). Conclusions: During the treatment period, HRQoL remained stable for most functional and symptom scales in both arms, suggesting that HRQoL is largely maintained with FTD/TPI. Treatment with FTD/TPI was associated with a positive trend toward a lower risk of QoL deterioration than placebo across all scales. Changes in QoL were informative for patients ‘expected ECOG status. Clinical trial information: NCT02500043.
Collapse
Affiliation(s)
- Maria Alsina
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Josep Tabernero
- Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain
| | - Kohei Shitara
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Toshihiko Doi
- National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | - Hendrik-Tobias Arkenau
- Sarah Cannon Research Institute, University College London Cancer Centre, London, United Kingdom
| | | | | | - Catia Faustino
- Instituto Portugues de Oncologia do Porto (IPO Porto), Porto, Portugal
| | - Vera Gorbunova
- N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | - Edvard Zhavrid
- N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | | | - Takayuki Ando
- Third Department of Internal Medicine, University of Toyama, Toyama, Japan
| | - Suayib Yalcin
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| | - Eric Van Cutsem
- University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium
| | - Donia Skanji
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Catherine Leger
- Institut de Recherches Internationales Servier, Suresnes, France
| | | | | |
Collapse
|
10
|
Ilson DH, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience PC, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci DV, Winkler RE, Makris L, Doi T, Shitara K. Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.4_suppl.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3 Background: The phase 3 study TAGS demonstrated that the novel oral therapy FTD/TPI (TAS-102) represents an effective treatment option with a manageable safety profile for pts with heavily pretreated mGC. In an earlier single-arm Japanese phase 2 trial in mGC, no differences were found in the pharmacokinetics of either FTD or TPI in pts with or without prior gastrectomy. We evaluated the efficacy and safety of FTD/TPI in pts with or without prior gastrectomy within the TAGS study. Methods: In this global phase 3 study of adult pts with mGC who had received ≥ 2 prior regimens of chemotherapy, pts were randomized 2:1 to receive FTD/TPI (35 mg/m2 BID on days 1–5 and 8–12 of each 28-day cycle) or placebo, plus best supportive care. We performed a preplanned analysis of efficacy and safety endpoints in pt subgroups with or without prior gastrectomy. Results: Of 507 randomized pts, 221 (44%) had a prior gastrectomy (FTD/TPI, 147/337; placebo, 74/170). Baseline pt characteristics were balanced across pt subgroups. FTD/TPI prolonged survival versus placebo regardless of gastrectomy (table). The frequency of neutropenia/leukopenia appeared to be higher among FTD/TPI-treated pts with vs without gastrectomy, but this did not result in more treatment discontinuations (table). Conclusions: In the TAGS study, subgroup analysis demonstrated that FTD/TPI is an effective treatment option with a manageable safety profile for pts with heavily pretreated mGC, regardless of prior gastrectomy. Clinical trial information: NCT02500043. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Wasat Mansoor
- The Christie NHS Foundation Trust Hospital, Manchester, United Kingdom
| | - Edvard Zhavrid
- Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
| | - Maria Alsina
- Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain
| | - Ben George
- Medical College of Wisconsin, Milwaukee, WI
| | | | | | | | | | | |
Collapse
|
11
|
Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol 2018; 5:e543-e553. [PMID: 30389036 DOI: 10.1016/s2352-3026(18)30157-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 08/31/2018] [Accepted: 09/10/2018] [Indexed: 01/25/2023]
Abstract
BACKGROUND Studies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharmacokinetics to rituximab. We aimed to assess the therapeutic equivalence of single-agent CT-P10 and rituximab in patients with newly diagnosed low-tumour burden follicular lymphoma. METHODS In this ongoing, randomised, double-blind, parallel-group, active-controlled, phase 3 trial, adult patients (≥18 years) with stage II-IV low-tumour-burden follicular lymphoma were randomly assigned (1:1) using an interactive web or voice response system stratified by region, stage, and age to CT-P10 or US-sourced rituximab. Patients received CT-P10 or rituximab (375 mg/m2 intravenous) on day 1 of four 7-day cycles (induction period). Patients who had disease control after the induction period continued to a maintenance period of CT-P10 or rituximab administered every 8 weeks for six cycles and, if completed, a second year of maintenance therapy of additional CT-P10 (every 8 weeks for six cycles) was offered. The study was partially unmasked after database lock (Feb 23, 2018) for all data up to 7 months (before cycle 3 of the maintenance period). The primary endpoint was the proportion of patients who achieved an overall response by 7 months in the intention-to-treat population. Efficacy equivalence was shown if the two-sided 90% CIs for the treatment difference in the proportion of responders between CT-P10 and rituximab was within the equivalence margin of 17%. This trial is registered with ClinicalTrials.gov, number NCT02260804. FINDINGS Between Nov 9, 2015, and Jan 4, 2018, 402 patients were assessed for eligibility, of whom 258 were randomly assigned: 130 to CT-P10 and 128 to rituximab. 108 (83%) of 130 patients assigned to CT-P10 and 104 (81%) of 128 assigned to rituximab achieved an overall response by month 7 (treatment difference estimate 1·8%; 90% CI -6·43 to 10·20). Therapeutic equivalence was shown (90% CIs were within the prespecified margin of 17%). The most common grade 3 or 4 treatment-emergent adverse events were decreased neutrophil count (two grade 3 in the CT-P10 group) and neutropenia (one in each group); all other grade 3 or 4 treatment-emergent adverse events occurred in one patient each. Six (5%) of 130 patients who received CT-P10 and three (2%) of 128 who received rituximab experienced at least one treatment-emergent serious adverse event. INTERPRETATION CT-P10 was equivalent to rituximab in terms of efficacy and was well tolerated. CT-P10 monotherapy is suggested as a new therapeutic option for patients with low-tumour-burden follicular lymphoma. FUNDING Celltrion, Inc.
Collapse
MESH Headings
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antibodies, Monoclonal, Murine-Derived/pharmacokinetics
- Antibodies, Monoclonal, Murine-Derived/pharmacology
- Antibodies, Monoclonal, Murine-Derived/therapeutic use
- Biosimilar Pharmaceuticals/adverse effects
- Biosimilar Pharmaceuticals/pharmacokinetics
- Biosimilar Pharmaceuticals/pharmacology
- Biosimilar Pharmaceuticals/therapeutic use
- Disease-Free Survival
- Double-Blind Method
- Female
- Humans
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/metabolism
- Lymphoma, Follicular/pathology
- Male
- Middle Aged
- Rituximab/adverse effects
- Rituximab/pharmacokinetics
- Rituximab/pharmacology
- Rituximab/therapeutic use
- Safety
- Treatment Outcome
- Tumor Burden/drug effects
Collapse
Affiliation(s)
- Michinori Ogura
- Department of Haematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan; School of Medicine, Fujita Medical University, Toyoake, Japan
| | - Juan Manuel Sancho
- Hematology Department, The Catalan Institute of Oncology-The Josep Carreras Leukaemia Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Seok-Goo Cho
- Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
| | - Hideyuki Nakazawa
- Department of Hematology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Junji Suzumiya
- Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan
| | - Gayane Tumyan
- Division of Hematology and Bone Marrow Transplantation, N N Blokhin Russian Cancer Research Center, Moscow, Russia
| | - Jin Seok Kim
- Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea
| | - Anne Lennard
- Northern Institute for Cancer Care, Newcastle University, Newcastle-upon-Tyne, UK
| | - José Mariz
- Department of Onco-Hematology, Portuguese Institute of Oncology, Porto, Portugal
| | - Nikolai Ilyin
- Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, St Petersburg, Russia
| | - Wojciech Jurczak
- Department of Haematology, Jagiellonian University, Kraków, Poland
| | | | - Olga Samoilova
- Department of Hematology, Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia
| | - Edvard Zhavrid
- N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Belarus
| | - Eduardo Yañez Ruiz
- Department of Internal Medicine, Universidad de la Frontera, Temuco, Chile
| | - Marek Trneny
- Department of Medicine, Charles University, General Hospital in Prague, Prague, Czech Republic
| | - Leslie Popplewell
- Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA
| | | | - Christian Buske
- Comprehensive Cancer Center Ulm, University Hospital of Ulm, Ulm, Germany
| | - Won-Seog Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | | | | | | | - Larry W Kwak
- Toni Stephenson Lymphoma Center and Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
| |
Collapse
|
12
|
Shitara K, Tabernero J, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Ganea D, Yalçın Ş, Fujitani K, Beretta G, Winkler R, Doi T, Ilson D. Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19:1437-1448. [DOI: 10.1016/s1470-2045(18)30739-3] [Citation(s) in RCA: 298] [Impact Index Per Article: 49.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Revised: 09/21/2018] [Accepted: 09/24/2018] [Indexed: 02/08/2023]
|
14
|
Tabernero J, Shitara K, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Ganea D, Yalçın Ş, Fujitani K, Beretta G, Winkler R, Makris L, Doi T, Ilson D. Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy208.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
15
|
Kim W, Coiffier B, Buske C, Ogura M, Kwak L, Jurczak W, Sancho J, Zhavrid E, Kim J, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Lee S, Lee S, Bae Y. CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx664.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Esteva F, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Zautashvili Z, Morar-Bolba G, Li R, Lifirenko I, Rusyn A, Lee S, Yu S, Stebbing J. Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; 4:e362-e373. [PMID: 28712940 DOI: 10.1016/s2352-3026(17)30120-5] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 06/14/2017] [Accepted: 06/14/2017] [Indexed: 01/19/2023]
Abstract
BACKGROUND Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-inferior efficacy and pharmacokinetic equivalence of CT-P10 compared with rituximab, when used in combination with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed advanced-stage follicular lymphoma. METHODS In this ongoing, randomised, double-blind, parallel-group, active-controlled study, patients aged 18 years or older with Ann Arbor stage III-IV follicular lymphoma were assigned 1:1 to CVP plus intravenous infusions of 375 mg/m2 CT-P10 or rituximab on day 1 of eight 21-day cycles. Randomisation was done by the investigators using an interactive web or voice response system and a computer-generated randomisation schedule, prepared by a clinical research organisation. Randomisation was balanced using permuted blocks and was stratified by country, gender, and Follicular Lymphoma International Prognostic Index score (0-2 vs 3-5). Study teams from the sponsor and clinical research organisation, investigators, and patients were masked to treatment assignment. The study was divided into two parts: part 1 assessing equivalence of pharmacokinetics (in the pharmacokinetics subset), and part 2 assessing efficacy in all randomised patients (patients from the pharmacokinetics subset plus additional patients enrolled in part 2). Equivalence of pharmacokinetics was shown if the 90% CIs for the geometric mean ratio of CT-P10 to rituximab in AUCτ and CmaxSS were within the bounds of the equivalence margin of 80% and 125%. Non-inferiority of response was shown if the one-sided 97·5% CI lay on the positive side of the -7% margin, using a one-sided test done at the 2·5% significance level. The primary efficacy endpoint was the proportion of patients who had an overall response over eight cycles and was assessed in the efficacy population (all randomised patients). The primary pharmacokinetic endpoints were area under the serum concentration-time curve at steady state (AUCτ) and maximum serum concentration at steady state (CmaxSS) at cycle 4, assessed in the pharmokinetic population. This trial is registered with ClinicalTrials.gov, number NCT02162771. FINDINGS Between July 28, 2014, and Dec 29, 2015, 140 patients were enrolled. Here we report data for the eight-cycle induction period, up to week 24. The proportion of patients with an overall response in the efficacy population was 64 (97·0%) of 66 patients in the CT-P10 treatment group and 63 (92·6%) of 68 patients in the rituximab treatment group (4·3%; one-sided 97·5% CI -4·25), which lay on the positive side of the predefined non-inferiority margin. The ratio of geometric least squares means (CT-P10/rituximab) was 102·25% (90% CI 94·05-111·17) for AUCτ and 100·67% (93·84-108·00) for CmaxSS, with all CIs within the bioequivalence margin of 80-125%. Treatment-emergent adverse events were reported for 58 (83%) of 70 patients in the CT-P10 treatment group and 56 (80%) of 70 in the rituximab treatment group. The most common grade 3 or 4 treatment-emergent adverse event in each treatment group was neutropenia (grade 3, 15 [21%] of 70 patients in the CT-P10 group and seven [10%] of 70 patients in the rituximab group). The proportion of patients who experienced at least one treatment-emergent serious adverse event was 16 (23%) of 70 patients in the CT-P10 group and nine (13%) of 70 patients in the rituximab group. INTERPRETATION In this study, we show that CT-P10 exhibits non-inferior efficacy and pharmacokinetic equivalence to rituximab. The safety profile of CT-P10 was comparable to that of rituximab. CT-P10 might represent a new therapeutic option for advanced-stage follicular lymphoma. FUNDING Celltrion, Inc.
Collapse
Affiliation(s)
- Won Seog Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Christian Buske
- Comprehensive Cancer Center Ulm, University Hospital of Ulm, Ulm, Germany
| | - Michinori Ogura
- Department of Haematology, Tokai Central Hospital, Kakamigahara, Gifu, Japan
| | - Wojciech Jurczak
- Department of Haematology, Jagiellonian University, Kraków, Poland
| | - Juan-Manuel Sancho
- Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain
| | - Edvard Zhavrid
- N N Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Minsk, Belarus
| | - Jin Seok Kim
- Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea
| | | | | | - Mariana Vasilica
- Hematology Department, Fundeni Clinical Institute, Bucharest, Romania
| | | | | | - Larry W Kwak
- Toni Stephenson Lymphoma Center and Department of Haematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA
| | | | | | | | | |
Collapse
|
18
|
Buske C, Kim W, Kwak L, Coiffier B, Jurczak W, Sancho J, Zhavrid E, Kim J, Hernández Rivas J, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Lee S, Lee S, Bae Y, Ogura M. A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_83] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Buske
- CCC Ulm; University Hospital of Ulm; Ulm Germany
| | - W. Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Republic of Korea
| | - L. Kwak
- Toni Stephenson Lymphoma Center and Department of Haematology and Hematopoietic Cell Transplantation, City of Hope Duarte; Duarte USA
| | - B. Coiffier
- Department of Hematology; Hospices Civils de Lyon; Lyon France
| | - W. Jurczak
- Department of Haematology; Jagiellonian University; Kraków Poland
| | - J.M. Sancho
- Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol; Badalona Spain
| | - E. Zhavrid
- Department of Haematology; N.N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology; Minsk Belarus
| | - J. Kim
- Department of Internal Medicine; Yonsei University College of Medicine, Severance Hospital; Seoul Korea, Republic of
| | | | - A. Prokharau
- Department of Haematology, Minsk City Clinical Oncology Dispensary; Minsk Belarus
| | - M. Vasilica
- Hematology Department; Fundeni Clinical Institute; Bucharest Romania
| | - R. Nagarkar
- Curie Manavata Cancer Centre, Curie Manavata Cancer Centre; Maharashtra India
| | - D. Osmanov
- Department of Chemotherapy of Hemoblastosis, N.N. Blokhin Russian Cancer Research Center; Moscow Russian Federation
| | - S. Lee
- Clinical Development Division; CELLTRION, Inc.; Incheon Korea, Republic of
| | - S. Lee
- Clinical Development Division; CELLTRION, Inc.; Incheon Korea, Republic of
| | - Y. Bae
- Clinical Development Division; CELLTRION, Inc.; Incheon Korea, Republic of
| | - M. Ogura
- Department of Haematology, Tokai Central Hospital, Kakamigahara; Gifu Japan
| |
Collapse
|
19
|
Talayeva S, Kaidarova D, Zhavrid E, Prokharau A, Antonenkova N, Shatkovskaya O, Manasheva A, Rutzhanova Z. Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study. Breast 2017. [DOI: 10.1016/s0960-9776(17)30116-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
20
|
Kharuzhyk S, Zhavrid E, Sachivko N. Using diffusion-weighted MRI derived apparent diffusion coefficient as a predictive biomarker of tumor response in non-Hodgkin lymphoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.80] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Baranau Y, Zhavrid E, Petrovitch S, Sachivko N, Zhuravkin I. 9338 Experience in administration of high-dose interleukin-2 immunotherapy in combination with chemotherapy for disseminated skin melanoma management. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71982-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
22
|
Siarheyeva V, Petrovitch S, Zhavrid E, Istomin Y, Baranau Y, Mazurenko A, Alexandrova E, Zhuravkin I. 8041 Preliminary results of whole-body hyperthermia in combination with oxaliplatin in patients with platinum-resistant/refractory ovarian cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71563-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
23
|
Petrovitch S, Zhavrid E, Aleinikova O, Kiselev L, Strongin Y, Baranau Y, Demidovich E, Minailo I, Belotserkovskaya M, Stuk N. 9428 Experience in high-dose chemotherapy with peripheral stem cell rescue and biotherapy for young adults with high-risk Ewing/PNET sarcoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72016-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Konoplya N, Sachivko N, Zhavrid E. Alterations in functional activity of thyroid parafollicular cells in the course of chemoradiotherapy of children with Hodgkin's disease. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81759-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Zhavrid E, Fradkin S, Sachivko N, Hodina T. Pilot study of reaferon R-IFN-2A (R), adriamycin (ADR) and whole - body hyperthermia (WBH) in patients with metastatic renal cell carcinoma (RCC): Preliminary results. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91940-m] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Zhavrid E, Kostenich G, Zhuravkin I. Photodynamic therapy (PDT) with chlorins. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91809-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|